Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVES: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials.
METHODS: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts.
RESULTS: Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use.
CONCLUSIONS: G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
The Journal of antimicrobial chemotherapy - 78(2023), 10 vom: 03. Okt., Seite 2591-2596 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gonzalez-Serna, Alejandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2WU922TK3L |
|---|
| Anmerkungen: |
Date Completed 04.10.2023 Date Revised 11.01.2024 published: Print ClinicalTrials.gov: NCT02333292, NCT02057003 Citation Status MEDLINE |
|---|
| doi: |
10.1093/jac/dkad278 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361694954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361694954 | ||
| 003 | DE-627 | ||
| 005 | 20240114233743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jac/dkad278 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM361694954 | ||
| 035 | |a (NLM)37671831 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gonzalez-Serna, Alejandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2023 | ||
| 500 | |a Date Revised 11.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02333292, NCT02057003 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials | ||
| 520 | |a METHODS: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts | ||
| 520 | |a RESULTS: Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use | ||
| 520 | |a CONCLUSIONS: G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a glecaprevir |2 NLM | |
| 650 | 7 | |a K6BUU8J72P |2 NLM | |
| 650 | 7 | |a pibrentasvir |2 NLM | |
| 650 | 7 | |a 2WU922TK3L |2 NLM | |
| 700 | 1 | |a Corma-Gomez, Anaïs |e verfasserin |4 aut | |
| 700 | 1 | |a Tellez, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Corona-Mata, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Rios-Villegas, María Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Galera, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Collado-Romacho, Antonio Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a De Los Santos, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Cucurull, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a García-Martín, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Real, Luis Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Macias, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 78(2023), 10 vom: 03. Okt., Seite 2591-2596 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:10 |g day:03 |g month:10 |g pages:2591-2596 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkad278 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 10 |b 03 |c 10 |h 2591-2596 | ||